stockportfolio.pro
Stocks / CATX vs EMBC
CATX vs EMBC
Perspective Therapeutics, Inc. and Embecta Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Perspective Therapeutics, Inc. (CATX) | Embecta Corp. (EMBC) | |
|---|---|---|
| Market cap | $0.3B | $0.2B |
| Revenue (latest FY) | $884,000 | $1.08B |
| Net income (latest FY) | $-103.12M | $95.40M |
| Revenue growth (5y CAGR) | -38.5% | -0.1% |
| Net margin | -11665.3% | 8.8% |
| Return on equity | -49.8% | -14.7% |
| P/E ratio | — | 1.7 |
| Dividend yield | — | 13.9% |
| Profitable years (of last 10) | 0 | 6 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CATX — free Open EMBC — freeFrequently asked questions
Which is bigger, CATX or EMBC?
Perspective Therapeutics, Inc. is larger by market capitalization — $0.3B versus $0.2B.
Which grows faster, CATX or EMBC?
Over the last five fiscal years, Embecta Corp. grew revenue faster — -0.1%/yr versus -38.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.